Safety of anacetrapib in patients with or at high risk for coronary heart disease.

  title={Safety of anacetrapib in patients with or at high risk for coronary heart disease.},
  author={Christopher P. Cannon and Sukrut Shah and Hayes M. Dansky and Michael H. Davidson and Eliot A. Brinton and Antonio M. Jr. Gotto and Michael E Stepanavage and Sherry Xueyu Liu and Patrice Gibbons and Tanya B Ashraf and Jennifer Zafarino and Yale B. Mitchel and Philip John Barter},
  journal={The New England journal of medicine},
  volume={363 25},
BACKGROUND Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol. METHODS We conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety profile of anacetrapib in patients with coronary heart disease or at high risk for coronary heart disease. Eligible patients who were taking a statin and who had an LDL cholesterol level that was consistent… 

Tables from this paper

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events.

Cardiovascular outcomes trial with anacetrapib in subjects with high cardiovascular risk – are major benefits REVEALed?

  • S. Doggrell
  • Biology
    Expert opinion on pharmacotherapy
  • 2018
The benefits of anacetrapib were not major, and may not apply in ‘real’ world populations where adherence to medicines is lower than in REVEAL, which demonstrated cardiovascular benefits, but not a reduction in coronary artery deaths.

Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study

Inhibition of cholesteryl ester transfer protein is a strategy under investigation for raising HDL cholesterol levels and addressing residual cardiovascular risk after effective reduction of LDL cholesterol, and anacetrapib is being evaluated in an ongoing cardiovascular outcomes trial.

Anacetrapib: A Potential New Therapy for Dyslipidemia

A cholesteryl ester transfer protein (CETP) inhibitor currently in Phase III of development as a treatment for those with dyslipidemia and the risk of cardiovascular disease, anacetrapib has been shown to raise HDL-C and decrease low-density lipoprotein cholesterol by up to 39% compared with placebo.

Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study

The results of the 2-year extension to the DEFINE study where patients continued on the same assigned treatment as in the original 76-week study were well tolerated with durable lipid-modifying effects on LDL-C and HDL-C.

Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?

Although anacetrapib appears to be safe and is effective in altering lipid-related biochemical parameters of interest, its effect on cardiovascular outcomes remains unknown and the results of the phase III REVEAL randomised controlled trial will be critical.



Effects of torcetrapib in patients at high risk for coronary events.

Although there was evidence of an off-target effect of torcetrapib, it cannot rule out adverse effects related to CETP inhibition, and the trial was terminated prematurely because of an increased risk of death and cardiac events.

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

In subjects with low HDL cholesterol levels, CETP inhibition with torcetrapib markedly increased HDL cholesterol Levels and also decreased LDL cholesterol Levels, both when administered as monotherapy and when administered in combination with a statin.

Association of Circulating Cholesteryl Ester Transfer Protein Activity With Incidence of Cardiovascular Disease in the Community

In a prospective investigation of a community-based sample, lower plasma CETP activity was associated with greater CVD risk, challenging the concept that CETP inhibition may lower CVDrisk.

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

In this study of patients with previous MI, intensive lowering of LDL-C did not result in a significant reduction in the primary outcome of major coronary events, but did reduce the risk of other composite secondary end points and nonfatal acute MI.

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

Dalcetrapib showed no clinically relevant differences vs. placebo in adverse events, laboratory parameters including aldosterone, electrocardiograms, and vital signs including blood pressure (BP); and had no measurable, clinically relevant effect on lymph node size.